Karolinska Development
 

View full portfolio and sort by:

   

Infectious Disease

Karolinska Development's projects within infectious diseases include malaria, which causes one million deaths each year, most of which are children1. Products against the most common invasive fungal infections, Aspergillus and Candida are also under development.

 

Concept Development Lead Discovery Lead Optimization Preclinical Development Phase I Phase II Phase III Launch

Dilaforette AB

Biosergen AS

First In Class Potential

Dilaforette AB

Severe malaria kills one million people every year, mostly children. Dilaforette is developing a heparin analogue, sevuparin, for the treatment of severe malaria that prevents infected cells’ ability to block blood vessels.

 
First In Class Potential

Biosergen AS

Biosergen develops new antibiotics for the treatment of fungal diseases.

www.biosergen.com
 
 

 

Source: 1) WHO, The Global Burden of Disease: 2004 Update, 2008